A recent study showed that programmed death-ligand 1 (PD-L1) expression and T-cell infiltration in patients with EGFR–mutant non-small cell lung cancer are related to immunotherapy (Chen et al., 2020). Here, EGFR is linked to non-small cell lung carcinoma.